Trials / Completed
CompletedNCT01365546
Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery
Prospective, Open-Label, Multi-Center, Phase III CLinical Study to Investigate the Efficacy and Safety of Human Factor VWF/FVIII Concentrate (Wilate) in Subjects With Inherited Von Willebrand Disease Who Undergo Surgical Procedures
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Octapharma · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | human VWF/FVIII concentrate | intravenous infusion. Dose based on subject's individual invivo-recovery |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2014-02-01
- Completion
- 2014-04-01
- First posted
- 2011-06-03
- Last updated
- 2015-03-09
- Results posted
- 2015-03-09
Locations
15 sites across 9 countries: United States, Bulgaria, India, Italy, Oman, Poland, Romania, South Africa, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01365546. Inclusion in this directory is not an endorsement.